장
장부환 Chairman & CEO
C-suite M
KR KR · DART (FSS)
Explore the full record of transactions filed by 장부환, Chairman & CEO. Officer active across 2 companies, notably 비보존 제약. In total, 18 disclosures have been logged. The latest transaction was disclosed on 30 April 2026 — Purchase. Regulator: DART (FSS). The full history is free.
Declarations 18 total
€1m 277,778 shares @ €5.202 0.0007% mcap 100.0% of flow
DART:20260507000560 · 30 Apr 2026
Ideal exit: 25 Jan 2027 (T+270) DART:20260415000525 · 15 Apr 2026
Ideal exit: 10 Jan 2027 (T+270) DART:20260415000508 · 15 Apr 2026
Ideal exit: 10 Jan 2027 (T+270) €314,335 180,954 shares
DART:20260409002937 · 9 Apr 2026
DART:20260406003902 · 6 Apr 2026
Ideal exit: 1 Jan 2027 (T+270) €936,437 180,954 shares @ €5.175 0.0005% mcap 100.0% of flow
DART:20260403003027 · 31 Mar 2026
Ideal exit: 26 Dec 2026 (T+270) 0
DART:20260331003925 · 31 Mar 2026
0
DART:20260323001067 · 23 Mar 2026
€6,474 6,694 shares @ €1.8022 0.0000% mcap 100.0% of flow
DART:20260312000416 · 5 Mar 2026
Ideal exit: 30 Nov 2026 (T+270) €2,332 3,531 shares @ €1.8022 0.0000% mcap 100.0% of flow
DART:20260312001284 · 5 Mar 2026
Ideal exit: 30 Nov 2026 (T+270) €5,141 2,218 shares
DART:20260312001007 · 12 Mar 2026
Ideal exit: 7 Dec 2026 (T+270) €962,250 1,067,850 shares @ €1.8022 0.0005% mcap 100.0% of flow
DART:20260312000892 · 5 Mar 2026
Ideal exit: 30 Nov 2026 (T+270) €29,241 30,232 shares @ €1.8022 0.0000% mcap 100.0% of flow
DART:20260312000316 · 5 Mar 2026
Ideal exit: 30 Nov 2026 (T+270) €907 938 shares @ €1.8022 0.0000% mcap 100.0% of flow
DART:20260312000131 · 5 Mar 2026
Ideal exit: 30 Nov 2026 (T+270) €434 452 shares @ €1.8022 0.0000% mcap 100.0% of flow
DART:20260312000032 · 5 Mar 2026
Ideal exit: 30 Nov 2026 (T+270) €1,371 1,419 shares @ €1.8022 0.0000% mcap 100.0% of flow
DART:20260311003307 · 5 Mar 2026
Ideal exit: 30 Nov 2026 (T+270) €19,244 19,897 shares @ €1.8022 0.0000% mcap 100.0% of flow
DART:20260311003174 · 5 Mar 2026
Ideal exit: 30 Nov 2026 (T+270) €4,390 4,540 shares @ €1.8022 0.0000% mcap 100.0% of flow
DART:20260311003296 · 5 Mar 2026
Ideal exit: 30 Nov 2026 (T+270) About 장부환 Jang Boo-hwan is the Chairman & CEO of VIVOCON Pharmaceuticals, a company specializing in drug development. Under his leadership, the company focuses on innovation and expanding its product portfolio, aiming to improve patients' quality of life through advanced therapeutic solutions.